

Edgar Filing: ELAN CORP PLC - Form SC 13G/A

ELAN CORP PLC  
Form SC 13G/A  
February 11, 2004

SCHEDULE 13G

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G/A1

Under the Securities Exchange Act of 1934  
(Amendment No. 1)\*

DOV Pharmaceutical, Inc.

-----  
(Name of Issuer)

Common Stock, par value \$.0001 per Share

-----  
(Title of Class of Securities)

259858108

-----  
(CUSIP Number)

December 31, 2003

-----  
(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

/ / Rule 13d-1(b)  
/ / Rule 13d-1(c)  
/X/ Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Edgar Filing: ELAN CORP PLC - Form SC 13G/A

1. Names of Reporting Persons.

I.R.S. Identification Nos. of above persons (entities only).

Elan Corporation, plc

2. Check the Appropriate Box if a Member of a Group  
(See Instructions)

(a) / /

(b) / /

3. SEC Use Only

4. Citizenship or Place of Organization

Ireland

5. Sole Voting Power

0

Number of  
Shares  
Beneficially

6. Shared Voting Power

4,150,511

Owned by Each  
Reporting  
Person With:

7. Sole Dispositive Power

0

8. Shared Dispositive Power

4,150,511

9. Aggregate Amount Beneficially Owned by Each Reporting Person

4,150,511

10. Check box if the Aggregate Amount in Row (9) Excludes Certain Shares  
(See Instructions)

/ /

11. Percent of Class Represented by Amount in Row (9)

20.7%

12. Type of Reporting Person (See Instructions)

CO

CUSIP 259858108

SCHEDULE 13G

-3-

1. Names of Reporting Persons.

Edgar Filing: ELAN CORP PLC - Form SC 13G/A

I.R.S. Identification Nos. of above persons (entities only).

Elan International Services, Ltd.

2. Check the Appropriate Box if a Member of a Group  
(See Instructions)

(a) / /  
(b) / /

3. SEC Use Only

4. Citizenship or Place of Organization

Bermuda

5. Sole Voting Power

0

Number of  
Shares  
Beneficially

6. Shared Voting Power

4,150,511

Owned by Each  
Reporting  
Person With:

7. Sole Dispositive Power

0

8. Shared Dispositive Power

4,150,511

9. Aggregate Amount Beneficially Owned by Each Reporting Person

4,150,511

10. Check box if the Aggregate Amount in Row (9) Excludes Certain Shares  
(See Instructions)

/ /

11. Percent of Class Represented by Amount in Row (9)

20.7%

12. Type of Reporting Person (See Instructions)

CO

CUSIP 259858108

SCHEDULE 13G

-4-

1. Names of Reporting Persons.

I.R.S. Identification Nos. of above persons (entities only).

Elan Pharmaceutical Investments, Ltd.

Edgar Filing: ELAN CORP PLC - Form SC 13G/A

2. Check the Appropriate Box if a Member of a Group  
(See Instructions)

(a) / /  
(b) / /

-----  
3. SEC Use Only  
-----

4. Citizenship or Place of Organization

Bermuda  
-----

5. Sole Voting Power

0  
-----

Number of  
Shares  
Beneficially

6. Shared Voting Power

1,221,046  
-----

Owned by Each  
Reporting  
Person With:

7. Sole Dispositive Power

0  
-----

8. Shared Dispositive Power

1,221,046  
-----

9. Aggregate Amount Beneficially Owned by Each Reporting Person

1,221,046  
-----

10. Check box if the Aggregate Amount in Row (9) Excludes Certain Shares  
(See Instructions)

/ /  
-----

11. Percent of Class Represented by Amount in Row (9)

7.1%  
-----

12. Type of Reporting Person (See Instructions)

CO  
-----

CUSIP 259858108

SCHEDULE 13G

-5-

Item 1(a). Name of Issuer:

DOV Pharmaceutical, Inc.

Item 1(b). Address of Issuer's Principal Executive Offices:

433 Hackensack Avenue, Hackensack, New Jersey 07601

Item 2(a). Name of Person Filing:

## Edgar Filing: ELAN CORP PLC - Form SC 13G/A

This statement is filed on behalf of each of the following persons (collectively, the "Reporting Persons")

- (i) Elan Corporation, plc
- (ii) Elan International Services, Ltd.
- (iii) Elan Pharmaceutical Investments, Ltd.

Item 2(b). Address of Principal Business Office:

- (i) Elan Corporation, plc  
Lincoln House, Lincoln Place  
Dublin 2, Ireland
- (ii) Elan International Services, Ltd.  
102 St. James Court  
Flatts, Smiths FL 04  
Bermuda
- (iii) Elan Pharmaceutical Investments, Ltd. 102 St. James Court  
Flatts, Smiths FL 04  
Bermuda

Item 2(c). Citizenship:

- (i) Elan Corporation, plc is an Irish public limited company
- (ii) Elan International Services, Ltd. is a Bermuda exempted limited liability company
- (iii) Elan Pharmaceutical Investments, Ltd. is a Bermuda exempted limited liability company

Item 2(d). Title of Class of Securities:

Common Stock, par value \$.0001 per share (the "Shares")

Item 2(e). CUSIP Number:

259858108

Item 3. If this statement is filed pursuant to ss.ss.240.13d-1(b) or 240.13d-2(b) or (c), check whether the person is a:

This Item 3 is not applicable

CUSIP 259858108

SCHEDULE 13G

-6-

Item 4. Ownership:

Elan Corporation plc

(a) Amount beneficially owned as of February 11, 2004:

4,15

Edgar Filing: ELAN CORP PLC - Form SC 13G/A

- (b) Percent of class: 20.7%
- (c) Number of shares as to which such person has:
  - (i) sole power to vote or to direct the vote:
  - (ii) shared power to vote or to direct the vote: 4,15
  - (iii) sole power to dispose or to direct the disposition of:
  - (iv) shared power to dispose or to direct the disposition of: 4,15

Elan International Services, Ltd.

- (a) Amount beneficially owned as of February 11, 2004: 4,15
- (b) Percent of class: 20.7%
- (c) Number of shares as to which such person has:
  - (i) sole power to vote or to direct the vote:
  - (ii) shared power to vote or to direct the vote: 4,15
  - (iii) sole power to dispose or to direct the disposition of:
  - (iv) shared power to dispose or to direct the disposition of: 4,15

Elan Pharmaceutical Investments, Ltd.

- (a) Amount beneficially owned as of February 11, 2004: 1,22
- (b) Percent of class: 7.1%
- (c) Number of shares as to which such person has:
  - (i) sole power to vote or to direct the vote:
  - (ii) shared power to vote or to direct the vote: 1,22
  - (iii) sole power to dispose or to direct the disposition of:
  - (iv) shared power to dispose or to direct the disposition of: 1,22

CUSIP 259858108

SCHEDULE 13G

-7-

-----

- (1) 2,929,465 of the shares are beneficially owned directly by Elan International Services, Ltd., a direct wholly-owned subsidiary of Elan Corporation, plc, and 1,221,046 of the shares are beneficially owned directly by Elan Pharmaceutical Investments Ltd., a direct wholly-owned subsidiary of Elan International Services, Ltd.

CUSIP 259858108

SCHEDULE 13G

-8-

Edgar Filing: ELAN CORP PLC - Form SC 13G/A

Item 5. Ownership of Five Percent or Less of a Class:

Not Applicable

Item 6. Ownership of More than Five Percent on Behalf of Another Person:

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

Not Applicable

Item 8. Identification and Classification of Members of the Group:

Not Applicable

Item 9. Notice of Dissolution of Group:

Not Applicable

Item 10. Certifications:

Not Applicable.

CUSIP 259858108

SCHEDULE 13G

-9-

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 11, 2004

ELAN CORPORATION, PLC

By: /s/ William F. Daniel

-----  
Name: William F. Daniel  
Title: Executive Vice President  
and Secretary

Dated: February 11, 2004

ELAN INTERNATIONAL SERVICES, LTD.

By: /s/ Kevin Insley

-----  
Name: Kevin Insley  
Title: President and Chief  
Financial Officer

Dated: February 11, 2004

Edgar Filing: ELAN CORP PLC - Form SC 13G/A

ELAN PHARMACEUTICAL INVESTMENTS, LTD.

By: /s/ Kevin Insley

-----  
Name: Kevin Insley  
Title: President and Chief  
Financial Officer

CUSIP 259858108

SCHEDULE 13G

-10-

EXHIBIT INDEX

Page No.

A. Joint Filing Agreement dated February 11, 2004 by and among Elan Corporation, plc, Elan International Services, Ltd. and Elan Pharmaceutical Investments, Ltd.....11

CUSIP 259858108

SCHEDULE 13G

-11-

EXHIBIT A  
JOINT FILING AGREEMENT

The undersigned hereby agree that the statement on Schedule 13G with respect to the Common Stock of DOV Pharmaceutical, Inc., dated as of February 11, 2004 is, and any amendments thereto signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934.

Dated: February 11, 2004

ELAN CORPORATION, PLC

By: /s/ William F. Daniel

-----  
Name: William F. Daniel  
Title: Executive Vice President  
and Secretary

Dated: February 11, 2004

ELAN INTERNATIONAL SERVICES, LTD.

By: /s/ Kevin Insley

-----  
Name: Kevin Insley  
Title: President and Chief  
Financial Officer



Edgar Filing: ELAN CORP PLC - Form SC 13G/A

Dated: February 11, 2004

ELAN PHARMACEUTICAL INVESTMENTS, LTD.

By: /s/ Kevin Insley

-----  
Name: Kevin Insley  
Title: President and Chief  
Financial Officer